Literature DB >> 17716229

Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.

Daniel T Laskowitz1, Michael P Vitek.   

Abstract

The apolipoprotein E (apoE) polymorphism is emerging as a uniquely important genetic modifier that affects functional outcome from both acute and chronic neurological injuries. Recent attention has focused on common denominator mechanisms by which apoE might affect brain injury and/or brain repair responses in clinically diverse diseases. Although endogenous apoE likely serves several adaptive functions in the injured CNS, there is growing evidence that its effect on modifying brain inflammatory responses and providing protection from excitotoxic injury may be central to its protective properties. A more complete understanding of the role that apoE plays in the injured brain has led to novel therapeutic strategies for both acute and chronic neurological disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716229     DOI: 10.2217/14622416.8.8.959

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  29 in total

1.  The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage.

Authors:  Daniel T Laskowitz; Beilei Lei; Hana N Dawson; Haichen Wang; Steven T Bellows; Dale J Christensen; Michael P Vitek; Michael L James
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

2.  Apolipoprotein epsilon 4 genotype is associated with less improvement in cognitive function five years after cardiac surgery: a retrospective cohort study.

Authors:  Karsten Bartels; Yi-Ju Li; Yen-Wei Li; William D White; Daniel T Laskowitz; Miklos D Kertai; Mark Stafford-Smith; Mihai V Podgoreanu; Mark F Newman; Joseph P Mathew
Journal:  Can J Anaesth       Date:  2015-03-06       Impact factor: 5.063

3.  Age-dependent expression of apolipoprotein E in mouse cerebral cortex.

Authors:  Sarika Singh; Mahendra Kumar Thakur
Journal:  J Mol Neurosci       Date:  2010-06-24       Impact factor: 3.444

Review 4.  Pharmacogenomics in early-phase clinical development.

Authors:  Tal Burt; Savita Dhillon
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

Review 5.  Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury.

Authors:  Michael L James; Jordan M Komisarow; Haichen Wang; Daniel T Laskowitz
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

Review 6.  Cellular cholesterol homeostasis and Alzheimer's disease.

Authors:  Ta-Yuan Chang; Yoshio Yamauchi; Mazahir T Hasan; Catherine Chang
Journal:  J Lipid Res       Date:  2017-03-15       Impact factor: 5.922

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

8.  Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease.

Authors:  Svetlana Sarantseva; Svetlana Timoshenko; Olga Bolshakova; Eugenia Karaseva; Dmitry Rodin; Alexander L Schwarzman; Michael P Vitek
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

9.  Effect of human apolipoprotein E genotype on the pathogenesis of experimental ocular HSV-1.

Authors:  Partha S Bhattacharjee; Donna M Neumann; Timothy P Foster; Saadallah Bouhanik; Christian Clement; Dass Vinay; Hilary W Thompson; James M Hill
Journal:  Exp Eye Res       Date:  2008-05-18       Impact factor: 3.467

10.  Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage.

Authors:  Michael L James; Patrick M Sullivan; Christopher D Lascola; Michael P Vitek; Daniel T Laskowitz
Journal:  Stroke       Date:  2008-12-24       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.